Annexon (ANNX) Current Assets (2019 - 2026)
Annexon (ANNX) posted quarterly Current Assets of $228.3 million for Q1 2026, down 14.88% year-over-year from $268.2 million in Q1 2025, and down 5.75% quarter-over-quarter from $242.2 million in Q4 2025.
Annexon (ANNX) Current Assets (2019 - 2026) Analysis & Trends
Annexon's Current Assets history runs 8 years deep, the most recent figure standing at $228.3 million for Q1 2026.
- In Q1 2026, Current Assets fell 14.88% year-over-year to $228.3 million; the TTM figure through Mar 2026 stood at $228.3 million (down 14.88% YoY), while the FY2025 annual figure was $242.2 million, down 23.47% from the prior year.
- Current Assets for Q1 2026 stood at $228.3 million, down from $242.2 million in the prior quarter.
- The five-year high for Current Assets was $374.0 million in Q2 2024, with the low at $169.2 million in Q3 2023.
- The 5-year median for Current Assets is $242.2 million (2025), against an average of $249.8 million.
- The sharpest annual moves came in 2024 and 2025: Current Assets soared 103.52% in 2024, then tumbled 43.99% in 2025.
- Annexon's Current Assets stood at $248.1 million in 2022, then climbed by 6.35% to $263.9 million in 2023, then increased by 19.94% to $316.5 million in 2024, then fell by 23.47% to $242.2 million in 2025, then retreated by 5.75% to $228.3 million in 2026.
- Business Quant data shows ANNX's Current Assets at $228.3 million in Q1 2026, $242.2 million in Q4 2025, and $192.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Annexon | 1.00 Bn | 1.00 Bn | - | 212.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 212.76 Mn |
| Mar 31, 2026 | 228.27 Mn |
| Dec 31, 2025 | 242.19 Mn |
| Sep 30, 2025 | 192.82 Mn |
| Jun 30, 2025 | 230.62 Mn |
| Mar 31, 2025 | 268.16 Mn |
| Dec 31, 2024 | 316.46 Mn |
| Sep 30, 2024 | 344.29 Mn |
| Jun 30, 2024 | 373.97 Mn |
| Mar 31, 2024 | 270.74 Mn |
| Dec 31, 2023 | 263.86 Mn |
| Sep 30, 2023 | 169.17 Mn |
| Jun 30, 2023 | 197.56 Mn |
| Mar 31, 2023 | 232.54 Mn |
| Dec 31, 2022 | 248.10 Mn |
| Sep 30, 2022 | 274.78 Mn |
| Jun 30, 2022 | 181.37 Mn |
| Mar 31, 2022 | 211.25 Mn |
| Dec 31, 2021 | 247.69 Mn |
| Sep 30, 2021 | 275.50 Mn |